Cargando…

Dose‐dependent inhibition of demyelination and microglia activation by IVIG

OBJECTIVE: Intravenous immunoglobulin (IVIG) is an established treatment for numerous autoimmune conditions. Clinical trials of IVIG for multiple sclerosis, using diverse dose regimens, yielded controversial results. The aim of this study is to dissect IVIG effector mechanisms on demyelination in an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Winter, Meike, Baksmeier, Christine, Steckel, Julia, Barman, Sumanta, Malviya, Manish, Harrer‐Kuster, Melanie, Hartung, Hans‐Peter, Goebels, Norbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099529/ https://www.ncbi.nlm.nih.gov/pubmed/27844029 http://dx.doi.org/10.1002/acn3.326

Ejemplares similares

Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy
por: Cornblath, David R, et al.
Publicado: (2022)

Modified recombinant human IgG1‐Fc is superior to natural intravenous immunoglobulin at inhibiting immune‐mediated demyelination
por: Baksmeier, Christine, et al.
Publicado: (2021)

Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes
por: Breiner, Ari, et al.
Publicado: (2019)

NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody
por: Malviya, Manish, et al.
Publicado: (2017)

Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
por: Blackhouse, Gord, et al.
Publicado: (2010)

Guanabenz modulates microglia and macrophages during demyelination
por: Thompson, Kaitlyn Koenig, et al.
Publicado: (2020)

Myelinating Co-Culture as a Model to Study Anti-NMDAR Neurotoxicity
por: Sabet, Mercedeh Farhat, et al.
Publicado: (2022)

Treatment of scleromyxedema with IVIg
por: Moser, David W, et al.
Publicado: (2012)

Multiple Sclerosis: Microglia, Monocytes, and Macrophage-Mediated Demyelination
por: Prineas, John W, et al.
Publicado: (2021)

Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response
por: Richard, Alexandra, et al.
Publicado: (2016)

Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease
por: Wang, Zhouping, et al.
Publicado: (2020)

Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg
por: Nguyen, Thy P., et al.
Publicado: (2014)

A Comparative Study of IVIG versus IVIG with IV Methylprednisolone in Guillain–Barre Syndrome
por: Bhattiprolu, Rahi Kiran, et al.
Publicado: (2020)

Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy
por: Romozzi, Marina, et al.
Publicado: (2021)

Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis
por: Berghoff, Stefan A., et al.
Publicado: (2021)

Dynamic response of microglia/macrophage polarization following demyelination in mice
por: Chu, Tianci, et al.
Publicado: (2019)

Cooling down VITT with IVIG
por: Lentz, Steven R.
Publicado: (2021)

Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease
por: Han, Chun-Ling, et al.
Publicado: (2018)

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
por: Merkies, Ingemar S.J., et al.
Publicado: (2019)

An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis
por: Amedonu, Elsie, et al.
Publicado: (2019)

Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases
por: Weil, Marie-Theres, et al.
Publicado: (2016)

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)
por: Zhang, Wei, et al.
Publicado: (2023)

Microglia Play a Major Role in Direct Viral-Induced Demyelination
por: Chatterjee, Dhriti, et al.
Publicado: (2013)

Endogenous neural stem cells modulate microglia and protect against demyelination
por: Brousse, Béatrice, et al.
Publicado: (2021)

IVIG regulates the survival of human but not mouse neutrophils
por: Schneider, Christoph, et al.
Publicado: (2017)

Eczematous reaction to IVIG for the treatment of dermatomyositis()()
por: Berk-Krauss, J., et al.
Publicado: (2018)

Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
por: Zhu, Xiao-Lu, et al.
Publicado: (2022)

Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: a retrospective study
por: Cai, Jiang Hui, et al.
Publicado: (2022)

IgG Glyco-Engineering to Improve IVIg Potency
por: Bruggeman, Christine W., et al.
Publicado: (2018)

Microglia P2X4 receptors as pharmacological targets for demyelinating diseases
por: Di Virgilio, Francesco, et al.
Publicado: (2018)

Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination
por: Moreno-García, Álvaro, et al.
Publicado: (2020)

Microglia response following acute demyelination is heterogeneous and limits infiltrating macrophage dispersion
por: Plemel, Jason R., et al.
Publicado: (2020)

Correlation between the Level of Inflammatory Cytokines and Prognosis in Children with IVIG-sensitive Kawasaki Disease and IVIG-resistant Kawasaki Disease
por: Zhang, Hao, et al.
Publicado: (2022)

IVIG Treatment and Prognosis in Guillain–Barré Syndrome
por: van Doorn, Pieter A., et al.
Publicado: (2010)

IVIG Effects on Erythrocyte Sedimentation Rate in Children
por: Salehzadeh, Farhad, et al.
Publicado: (2014)

Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?
por: De Groot, Anne S., et al.
Publicado: (2013)

Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
por: Hooper, John A.
Publicado: (2008)

Unraveling the mechanisms of IVIG immunotherapy in MIS-C
por: Ganigara, Madhusudan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ej8etdpigobggmnef8dh9vge0v